Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02545543 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,278
- Enrollment target
NCT02545543 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 2,278 participants.
The verdict
NCT02545543, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,278 participants
- Enrollment target
Study Summary
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 5 through 17 years of age.
Interventions
- BIOLOGICAL Comparator QIV
- BIOLOGICAL Seqirus QIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,278 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02545543
The ClinicalTrials.gov registry entry for NCT02545543 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Comparator QIV is the first listed.
NCT02545543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02545543 about?
NCT02545543 is a clinical study titled "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age". This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 5 through 17 years of ...
What is the current status of trial NCT02545543?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,278 participants. The study started on 2015-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02545543?
The interventions under investigation include: Comparator QIV (BIOLOGICAL), Seqirus QIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02545543?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.